Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Status:
Completed
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
To determine biomarker responses to Entresto™in patients with Heart Failure with preserved
Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute on Aging (NIA)
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan